HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
Graphical abstract
Highlights
► HSP90 inhibition by 17-AAG decreases cellular Rad51 expression. ► 17-AAG downregulates the DNA repair capacity of human lung cancer cells. ► Rad51 plays a protective role in 17-AAG-induced cytotoxicity.
Introduction
Homologous recombination repair pathway represents a novel target for cancer therapy. Rad51 is the major strand-transferase required for recombination (Helleday et al., 2008). Many different cancer-derived cell lines and primary tumors have been shown to overexpress Rad51 (Klein, 2008), which lead to worse clinical outcomes in lung cancer (Qiao et al., 2005). At the same time, the Rad51 down-regulated human lung cancer cells show increased sensitivity to DNA damaging drugs like mitomycin C, cisplatin, and gemcitabine (Ashworth, 2008, Bristow and Hill, 2008, Helleday et al., 2007, Ko et al., 2008). Very high levels of mutagenesis have been observed in Rad51d-deleted Chinese hamster ovarian cells (CHO) cells (Hinz et al., 2006). Thus, defects in Rad51 play an important role in carcinogenesis.
Heat shock protein 90 (HSP90) is a major molecular chaperone that promotes the maturation and conformational stabilization of many cellular proteins, collectively referred to as “client proteins”, which are involved in tumor progression and proliferative and survival signals (Pearl and Prodromou, 2006, Whitesell and Lindquist, 2005). The HSP90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin derivative (Sharp and Workman, 2006), binds a conserved ATP interaction pocket in the HSP90 NH2-terminal domain (Isaacs et al., 2003). In pre-clinical models, 17-AAG has activity against various human cancers, where it is highly selective in degrading HSP90-client oncoproteins (Waza et al., 2005).
The present study aimed to determine whether or not 17-AAG affected Rad51 expression in NSCLC, and the role of Rad51 in 17-AAG-induced cytotoxicity. The 17-AAG-mediated Rad51 down-regulation caused decreased DNA repair ability in two NSCLC cell lines, whereas the over-expression of Rad51 restored cell viability and DNA repair capacity in 17-AAG-treated human lung cancer cells. These suggest that Rad51 plays a protective role in 17-AAG-induced cytotoxicity. As such, this study also posited the hypothesis that silencing Rad51 expression might be a new target for sensitization of NSCLC cells to HSP90 inhibition.
Section snippets
Drugs and reagents
The 17-AAG was purchased from Sigma Chemical (St. Louis, MO), while U0126 was purchased from Calbiochem-Novabiochem (San Diego, CA). The specific phospho-ERK1/2(Thr202/Tyr204) and phospho-MKK1/2(Ser217/Ser221) antibodies were purchased from Cell Signaling (Beverly, MA). Rabbit polyclonal antibodies against HSP90(H-114) (sc-7947), ERK2(C-14) (sc-154), Rad51(H-92) (sc-8349), and Actin(I-19) (sc-1616) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell lines and culture
Human lung cell carcinoma A549 and
17-AAG decreased Rad51 protein and mRNA in a time- and dose-dependent manner
HSP90 inhibition caused the depletion of HSP90 clients by disrupting client chaperoning and targeting the clients for proteasomal degradation. Treatment of cells with an HSP90 inhibitor, 17-AAG, provided a rapid and simple assay to assess whether a given protein depended either directly or indirectly on HSP90 chaperoning activity. To evaluate whether components of the MKK1/2-ERK1/2-Rad51 signaling pathway required HSP90, sub-confluent A549 or H1975 human lung cancer cells were treated with
Discussion
HSP90 expression is increased in a number of malignancies (Tsutsumi and Neckers, 2007) and it is an important molecular chaperone for protein folding and proteolytic turnover of key regulators of cell growth and survival (Whitesell and Lindquist, 2005). In the present study, the results illustrate for the first time that 17-AAG-decreased cellular Rad51 expression plays a role in decreasing the DNA repair capacity and cell survival in NSCLC cells. Enforced Rad51 expression can restore cell
Conflicts of interest statement
None declared.
Acknowledgements
The authors wish to thank Dr. Jia-Ling Yang for the expression plasmids for transfection and Dr. Chiou for with the arachidin-1. This work was supported by a grant from the National Science Council of Taiwan (Grant NSC 99-2320-B-415-001-MY3) and the National Taiwan University Hospital, Hsin-Chu Branch, Taiwan (Grant HCH101-05).
References (40)
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
J. Biol. Chem.
(2003)Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl
J. Biol. Chem.
(1999)Induction of Rad51 protein levels by p38 MAPK decreases cytotoxicity and mutagenicity in benzo[a]pyrene-exposed human lung cancer cells
Toxicol. Appl. Pharmacol.
(2008)DNA double-strand break repair: from mechanistic understanding to cancer treatment
DNA Repair (Amst.)
(2007)Heat shock protein 90 as a molecular target for cancer therapeutics
Cancer Cell.
(2003)Therapeutic and diagnostic implications of Hsp90 activation
Trends Mol. Med.
(2004)The consequences of Rad51 overexpression for normal and tumor cells
DNA Repair (Amst.)
(2008)Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood
(2005)Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin
Biochem. Biophys. Res. Commun.
(2006)- et al.
Inhibitors of the HSP90 molecular chaperone: current status
Adv. Cancer Res.
(2006)